110.79 0.00 (0.00%)
After hours: 4:41PM EDT
|Bid||110.01 x 100|
|Ask||113.63 x 100|
|Day's Range||110.37 - 114.79|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||56.24|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||159.76|
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
Amgen would be better off stringing together small deals, rather than attempting a megamerger, an analyst suggested Monday.
Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.
NEW YORK, NY / ACCESSWIRE / March 16, 2018 / Alexion Pharmaceuticals saw a pop in its share price on Thursday after the company said its next-generation blood drug ALXN1210 held up well against its big ...
Stocks that moved substantially or traded heavily Thursday: Dollar General Corp., up $4.24 to $93.44 The discount retailer gave a strong yearly profit forecast. Mattel Inc., down 34 cents to $13.84 Toys ...
Alexion rocketed after its next-generation blood disease drug proved worthy when compared with its biggest moneymaker.
The good news from the clinical trial is for Alexion Pharmaceuticals, Inc.’s ALXN1210. This is a drug that is meant to treat complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria. According to Alexion Pharmaceuticals, Inc., ALXN1210 shows that it is able to treat its target patients without showing inferiority to Soliris.
Alexion Pharmaceuticals (ALXN) is rising on Thursday, thanks to positive data from a trial for drug candidate ALXN1210. Alexion said that ALXN1201 met its primary endpoint, demonstrating it is as effective as the current treatment for Paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Leerink's Geoffrey Porges reiterated an Outperform rating on the stock, writing that he isn't surprised by the positive outcome of the trial, and that even with the stock rising today, he thinks it's worth buying through the $140 to $150 range. Raymond James's Laura Chico also reiterated an Outperform rating, writing that the results are encouraging and that while there may be some debate about whether or not the drug is superior to existing treatments, she believes that the dosing interval "paired with solid efficacy creates a high competitive bar." SunTrust Robinson Humphrey's Yatin Suneja reiterated a Buy rating, writing that the news reduces Alexion's risk, while both setting a higher bar for competition and extending the durability of its franchise.
The latest earnings announcement Alexion Pharmaceuticals Inc’s (NASDAQ:ALXN) released in December 2017 revealed that the business experienced a robust tailwind, eventuating to a double-digit earnings growth of 10.99%. Investors mayRead More...
Wall Street's main indexes edged higher on Thursday as industrial stocks gained following three days of losses due to fears of trade war between China and the United States. The S&P industrial index was up 0.15 percent, helped by gains in Caterpillar and General Electric . The S&P 500 gained 0.12 percent to 2,752.75 and the Nasdaq Composite was down just 0.03 percent at 7,494.93.
Stocks opened higher Thursday as Alexion Pharmaceuticals and Dollar General scored early standout gains.
The Dow Jones Industrial Average was set to open higher on Thursday after three sessions of losses that were triggered by intensifying fears of a trade war with China. By 8:39 a.m. ET Dow, e-minis were up 80 points.
Shares of biotech Alexion Pharmaceuticals Inc. soared 11% in premarket trade Thursday, after the company announced positive results in a trial of a treatment for Paroxysmal nocturnal hemoglobinuria (PNH). ...
Alexion Pharmaceuticals Inc said its experimental drug, ALXN1210, met the main goal in a late-stage study in patients with a rare blood disorder. The drug, ALXN1210, was being tested against the company's ...
Alexion Pharmaceuticals, Inc. announced today that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, demonstrated non-inferiority to Soliris® in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria based on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase levels, a direct ...
A study published in the Journal of Accounting Research shows that female analysts issue bolder and more accurate forecasts.
Alexion Pharmaceuticals today announced that management will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 9:20 a.m., ET.